TRCT
LSBPW

Tower Research Capital (TRC)’s LakeShore Biopharma Warrants LSBPW Stock Holding History

Tower Research Capital (TRC)’s Portfolio LSBPW Stock Details LSBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-126
Closed -$11 – 6046
2024
Q2 		$11 Hold
126
– – ﹤0.01% 5600
2024
Q1 		$9 Hold
126
– – ﹤0.01% 5783
2023
Q4 		$5 Hold
126
– – ﹤0.01% 5872
2023
Q3 		$5 Hold
126
– – ﹤0.01% 5885
2023
Q2 		$6 Hold
126
– – ﹤0.01% 5973
2023
Q1 		$0 Buy
+126
New +$19 ﹤0.01% 6359

Other funds holding LSBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $122M AUM 362.1% 1-Year Est. Return
BP
BFAM Partners Northpoint, Hong Kong, Hong Kong $44K AUM 8.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $715M AUM 19.57% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

Tower Research Capital (TRC)'s LSBPW Position: Q3 2024 in Review

Tower Research Capital (TRC) sold out of LakeShore Biopharma Warrants (LSBPW) in Q3 2024, closing a stake of 126 shares — an estimated $11 sold.

Tower Research Capital (TRC) first reported a position in LSBPW in Q1 2023 and held it in 6 quarters. The position peaked at $11 in Q2 2024. 21 funds tracked by Wall St. Rank hold LSBPW as of Q3 2024.

  • Tower Research Capital (TRC) reported no remaining LakeShore Biopharma Warrants position as of Q3 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 126 LakeShore Biopharma Warrants shares in Q3 2024, an estimated $11.
  • Tower Research Capital (TRC) first reported a position in LakeShore Biopharma Warrants in Q1 2023 and held it in 6 quarters.
  • Tower Research Capital (TRC)'s LakeShore Biopharma Warrants position peaked at $11 in Q2 2024.
  • 21 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q3 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2024, filed 14 Nov 2024.